UCB's Global Corporate Website



In the European Union and in Great Britain, Bimzelx® (bimekizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Prescribing information - European Union

Prescribing information - Great Britain

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.